There are few markers which help you determine your cellular age and everything for preventive health like insulin sensitivity, lipo a, homocysteine. Can you list such
Reading File
Finding Sources
Searching PubMed
biological age biomarkers
Searching the Web
American Heart Association cardiovascular risk assessment lipoprotein(a) apoB hs-CRP guidelines 2025
There is no single blood test that gives your true “cellular age.” Biological-age clocks, such as DNA-methylation testing, are mainly research or consumer tools, not established replacements for standard preventive screening. A 2025 systematic review found substantial variation in how biological age is measured and interpreted (review).
For practical preventive health, focus on markers that change decisions and are interpreted with your age, sex, family history, blood pressure, waist circumference, lifestyle, and medications.
High-value core markers
| Domain | Useful markers | Why it matters |
|---|---|---|
| Metabolic health | Fasting glucose, HbA1c | Screens for prediabetes/diabetes |
| Insulin resistance | Fasting insulin plus fasting glucose, optionally HOMA-IR | Can suggest insulin resistance, but HOMA-IR is an estimate, not a diagnosis; an oral glucose tolerance test can be more informative in selected cases. |
| Lipids | Lipid panel: LDL-C, HDL-C, triglycerides, non-HDL-C | Main atherosclerotic cardiovascular risk assessment |
| Atherogenic particle burden | ApoB | Often more informative than LDL-C when triglycerides are high, metabolic syndrome is present, or LDL-C and non-HDL-C disagree |
| Genetic cardiovascular risk | Lipoprotein(a), or Lp(a) | Usually worth checking at least once in adulthood, especially with premature heart disease in the family. Lp(a) at or above 50 mg/dL, or 125 nmol/L, is considered a cardiovascular risk-enhancing factor in ACC/AHA guidance (review of guideline threshold). |
| Blood pressure | Home or clinic BP | One of the most actionable longevity and cardiovascular markers |
| Kidney health | Creatinine/eGFR and urine albumin-creatinine ratio | Detects kidney disease and vascular risk early |
| Liver-metabolic health | ALT, AST, GGT | Helps identify fatty liver, alcohol-related injury, medication effects, and metabolic risk |
| Body composition | Waist circumference, waist-to-height ratio, weight trend | Better reflects central adiposity than BMI alone |
Useful second-line markers
| Marker | When it is useful | Important limitation |
|---|---|---|
| hs-CRP | Refines cardiovascular risk in selected people, particularly if risk is uncertain | It rises with infections, injury, obesity, smoking, and autoimmune disease. Do not test during acute illness. A persistent level at least 2 mg/L is often considered a risk enhancer. |
| Homocysteine | Consider if B12/folate deficiency, malabsorption, premature vascular disease, thrombosis history, or certain medications are concerns | It is not a routine “longevity” marker. High values can reflect B12 or folate deficiency; treating a number without finding the cause is not useful. Very high levels can occur in homocystinuria and are linked with early vascular disease. Robbins & Kumar Basic Pathology, section “Additional Risk Factors,” lines 2697-2702. |
| Ferritin with iron studies | Fatigue, anemia evaluation, heavy periods, suspected iron overload, inflammation | Ferritin is also an inflammation marker, so it can be high without iron overload. |
| CBC | General baseline: anemia, abnormal white cells, platelet abnormalities | Nonspecific, but high clinical value and low cost |
| TSH, with free T4 if abnormal | Symptoms, thyroid history, pregnancy planning, arrhythmia, unexplained lipid changes | Not generally necessary to repeat frequently if normal and asymptomatic |
| Vitamin B12 | Vegan diet, metformin, acid-suppressing medication, neuropathy, anemia, GI disease | Serum B12 can occasionally be misleading; methylmalonic acid is used selectively |
| Vitamin D | Osteoporosis risk, malabsorption, very limited sun exposure, certain medications | Routine population-wide testing is often overused |
| Uric acid | Gout, kidney stones, metabolic syndrome, diuretic use | It is not a stand-alone cardiovascular-age measure |
“Cellular aging” or advanced tests
These can be interesting, but should not be the foundation of a preventive plan:
- DNA methylation / epigenetic age clocks: closest thing to a cellular-age estimate, but results are not yet standardized enough to direct medical treatment.
- Telomere length: highly variable and generally not clinically useful for an individual’s preventive care.
- GlycA, oxidized LDL, LP-PLA2, advanced lipoprotein particle testing: sometimes useful in specialist settings, but often do not change management beyond ApoB, Lp(a), standard lipids, blood pressure, and glycemic testing.
- Continuous glucose monitor in people without diabetes: may help behavior change for some, but single glucose spikes do not by themselves diagnose insulin resistance.
A sensible preventive panel
For a generally healthy adult wanting a well-rounded baseline, discuss:
- Blood pressure and waist circumference
- CBC
- Comprehensive metabolic panel: kidney function, electrolytes, liver enzymes
- HbA1c and fasting glucose
- Standard lipid panel plus ApoB
- Lp(a) once in adulthood
- Urine albumin-creatinine ratio
- hs-CRP only if it will help resolve cardiovascular-risk uncertainty
- TSH, ferritin/iron studies, B12, vitamin D only when symptoms, diet, medications, risk factors, or prior results support testing
For insulin sensitivity, fasting insulin/HOMA-IR can be added if there is central weight gain, high triglycerides, fatty liver, PCOS, strong family history of diabetes, or borderline glucose results. Insulin resistance is associated with lower HDL and higher LDL particle number, among other metabolic changes. Harrison’s Principles of Internal Medicine, 22e, “Insulin Resistance,” lines 182-188.
The most meaningful “biological age” signals are often not exotic tests: blood pressure, ApoB/non-HDL cholesterol, Lp(a), HbA1c/glucose, waist size, kidney function, exercise capacity, sleep, smoking status, and muscle strength.
Recent evidence warning: biomarker-based biological-age measures remain an active research area rather than validated clinical decision tools. See PMID 39938306.
This is a shared conversation. Sign in to Orris to start your own chat.